NB: This write-up focuses only on UnitedHealthcare, the payer segment, and doesn’t include anything on the Optum side of the house.
HTN’s View: UnitedHealthcare is well positioned heading into 2027 after prudent pruning in MA, with growth focused on HMO, C-SNPs, and D-SNPs, plus better-than-expected Medicaid performance. Commercial is the closest thing to a squeaky wheel, though systemic drivers are at play, and management characterized the 2027 selling season as strong, with Surest getting another name-drop.
UnitedHealthcare’s Q3 results and YoY comps demonstrated the rewards to a (relatively) smaller footprint focused on profitability
Q3 revenues were $86.3b, and membership was 48.3m (versus $87.1b and 50.1m in Q3 2025)
Employer & Individual Q3 revenues were $20.2b (versus $19.9b in Q3 2025), contracting in Q3 by 165k members due to employer attrition.
Medicare & Retirement Q3 revenues were $42.4b (versus $43.4b in Q3 2025), with Stars results in line with expectations and membership contraction of 935k since year-end 2025.
Community & State Q3 revenues were $23.7b (versus $23.8b in Q3 2025)
Q3 earnings from operations were $2.8 billion and operating margin was 3.3% (versus $1.8 billion and 2.1% in Q3 2025).
UHC is focused on “high-value HMO, chronic special needs, and dual special needs offerings” for 2027 AEP
After a retrenching year, management characterized its offerings as competitive with Bobby Hunter, CEO of Government Programs, seeing good growth potential. As was underscored several times on the call, the company is focused on D-SNP, C-SNP, and high-value HMO offerings.
The narrative tracks what HTN observed in our initial review of the MA Landscape file:
The commercial book is seeing accelerating trend, exceeding 11% this year, driven by NSA IDR payments, provider cost intensity, and high-cost specialty drugs
In what is becoming a standard section during payer earnings, the NSA IDR process and its impact on affordability featured heavily:
Of particular concern is the ongoing abuse of the No Surprises Act dispute process by a relatively small number of clinician groups and third-party organizations. Arbitration awards can approach nearly 6% of total medical spend in some regions, translating to billions of dollars in excess costs for consumers, employers, and the health system.
Outside of NSA IDR discussions, Brandon Quevas, CEO of the Commercial Business, shared an upbeat assessment of the 2027 selling season and mentioned Surest, UHC’s own alternative plan design.
Medicaid margins to come in ahead of expectations, moderately better than -1%
Mike Cotton, CEO of Medicaid, said membership and acuity were tracking within expectations and the trend was coming in moderately better than expected, with the ongoing hotspots familiar to every MCO: behavioral health services, specialty pharmacy services, HCBS, and inpatient, with margins returning to target in 2028. After Cotton fielded a question about Medicaid margin recovery, Steve Helmsley added that, in the long run, “Medicaid is a good, durable marketplace that will continue to grow.”
